Efficacy of Subcutaneous Infliximab in Acute Severe Ulcerative Colitis: a Multicenter Retrospective Study

Inclusion Criteria

• •Patient ≥ 18 years old
• •Diagnosis of acute severe ulcerative colitis according to Truelove Witts criteria
• •Patients treated with at least one injection of subcutaneous Infliximab after induction with two or three intravenous perfusions of Infliximab
• •Patients with a follow-up of at least 12 months after the first subcutaneous injection
• •12-month data available in medical records
• •Patient who has received full information about the organization of the research and who has not objected to his or her participation and to the use of his or her data.